#### **Supplementary Material**

#### **Principal Components Analysis**

Although an analysis of variance (ANOVA) can be used to assess within-platform vs. between-platform variability on a gene-by-gene basis, it cannot be performed to analyze multiple genes simultaneously. For this purpose, we used a multivariate approach based on principal components analysis (PCA) (1) as visualized by Partek Pro (v. 5) software to summarize within-platform vs. between platform variability across a multidimensional scale. Like the comparison of the distribution of Z-scores, making comparisons between platforms with PCA requires that we bring all measurement technologies to a single common scale. In order to achieve this, we further applied a van der Waerden's transformation to the expression values from each chip for a direct comparison of platforms. This transformation entails replacing the data with its ranks and then applying an inverse normal transformation to the result to give (in the absence of tied values) a perfectly normal distribution. Supplemental Figure 3a shows the first two principal components of the data, which account for most of the variability in the multidimensional dataset (34.9 + 37.3 = 72.2%). Although the points (arrays) in supplemental figure 3a are color-coded by platform the principal components are computed without regard to platform category. It is clear from supplemental figure 3a that the between-platform variability is much greater than the within-platform variability (the first PC largely separating the cDNA from the two oligonucleotide platforms, and the second PC separating all platforms, especially the two oligonucleotide platforms). Supplemental figure 3a reveals that any variability due to the treatment condition is clearly overshadowed by the platform effect. Supplemental figure 3b shows a dot plot of PC #3, which clearly does capture the treatment effect. Since PC #3 explains 8.5% of the variability of the entire data, there does seem to be an ability to distinguish differential expression due to the treatment after masking out platform effects.

#### **Contingency Table Analysis**

After modeling gene expression with an ANOVA model using a .001 alpha (Supplemental Table 6), we found that the Amersham assay detected the largest number of genes (117), the Agilent assay identified 67, and the Affymetrix assay found 34 differentially expressed genes. McNemar's test statistics computed for each of the three platform pairs indicated significant differences (p < .017) in the number of genes found to be differentially expressed by each of the technologies. This observed difference may reflect the different levels of experimental variability associated with each of the platforms as seen in figure 3. For two of the comparisons, the Fisher's exact test for association between the gene sets were significant (p < .017) demonstrating that agreement between the 2 platforms occurred in a manner that was non-random. However, when comparing the Amersham and Affymetrix gene lists, no significant (non-random) association could be found.

A subset of the genes in our lists exhibited statistically significant differential expression at an alpha cut-off of .001 with less than 2-fold differential expression. Since microarray technologies are frequently considered more accurate in detecting genes differentially expressed at levels greater than or equal to 2-fold (2), we applied an additional 2-fold change (in both directions) minimum criterion upon any genes found significant at a .001 alpha level to assess whether it would increase the level of overlap of differentially expressed genes detected by each platform. Despite applying this additional fold change criterion, we could not reject the null hypothesis (p < .017) of no association between the Amersham and Affymetrix gene lists (Supplemental Table 7). Only when the alpha cutoff was reduced

to .01 with a 2-fold minimum criterion courcomparisons (Supplemental Table 8).	ld we reject the	null hypothesis of no	association across all 2-way

**Supplemental Table 1:** Pearson's product-moment and Spearman's rank-order correlation coefficients of gene expression measurements from 3 commercial microarray technologies matched by their Unigene ID. P-values of the hypothesis of no correlation are also reported.

Comparison	Platform A	Platform B	Pearson's	P-value	Spearman's	P-value	N
1	Amersham	Agilent	0.54505	<.0001	0.54630	<.0001	8024
2	Amersham	Affymetrix	0.59118	<.0001	0.58727	<.0001	8024
3	Agilent	Affymetrix	0.56198	<.0001	0.55232	<.0001	8024

**Supplemental Table 2:** Pearson's product-moment and Spearman's rank-order correlation coefficients of the fold change of time 0 hours and time 24 hours measurements matched by their Unigene ID. P-values of the hypothesis of no correlation are also reported.

Comparison	Platform A	Platform B	Pearson's	P-value	Spearman's	P-value	N	
1	Amersham	Agilent	0.63374	<.0001	0.57991	<.0001	4012	
2	Amersham	Affymetrix	0.56066	<.0001	0.53731	<.0001	4012	
3	Agilent	Affymetrix	0.59903	<.0001	0.59549	<.0001	4012	

Supplemental Table 3: Contingency tables of differential gene expression classifications from data matched by

Unigene ID that was modeled with a mixed-model nested ANOVA and an alpha cut-off of .001. In each cell the frequency, row percentage, and column percentage is reported. Probability values from Fisher's Exact Test of association and McNemar's test of agreement are also reported.

Table of Agilent by Affymetrix					
	Affyn	netrix			
Agilent	No	Yes	Total		
No	3800	57 <sup>+</sup>	3857		
	98.52	1.48			
	96.50	77.03			
Yes	138 <sup>+</sup>	17*	155		
	89.03	10.97			
	3.50	22.97			
Total	3938	74	4012		

Table of Amersham by Affymetrix				
	Affyn	netrix		
Amersham	No	Yes	Total	
No	3693	57 <sup>+</sup>	3750	
	98.48	1.52		
	93.78	77.03		
Yes	245+	17*	262	
	93.51	6.49		
	6.22	22.97		
Total	3938	74	4012	

Table of Amersham by Agilent					
	Agi	lent			
Amersham	No	Yes	Total		
No	3650	100 <sup>+</sup>	3750		
	97.33	2.67			
	94.63	64.52			
Yes	207+	55*	262		
	79.01	20.99			
	5.37				
Total	3857	155	4012		

Platform A	Platform B	Exact P-value for McNemar's Test	Fisher's Exact Test P-value (Right)
Agilent	Affymetrix	<.0001	<.0001
Amersham	Affymetrix	<.0001	<.0001
Amersham	Agilent	<.0001	<.0001

<sup>\*</sup> significant non-random association

<sup>&</sup>lt;sup>+</sup> significantly different detection rates

**Supplemental Table 4:** Pearson's product-moment correlation coefficients of technical and biological replicate measurements. P-values of the hypothesis of no correlation are also reported.

Companicon	Platform	Technical	Biological P-value		P-value	N
Comparison	Flatioriii	Replicates	r-value	Replicates	r-value	17
1	Affymetrix	0.91894	<.0001	0.91255	<.0001	4018
2	Amersham	0.99259	<.0001	0.98240	<.0001	4018
3	Agilent	0.98727	<.0001	0.96435	<.0001	4018

**Supplemental Table 5:** Average difference of fold change measured by two platforms

Comparison	Platform A	Platform B	Mean Difference	N	<b>Std Dev</b>
1	Amersham	Agilent	0.0514661	2009	0.2502959
2	Agilent	Affymetrix	0.1033182	2009	0.3141808
3	Amersham	Affymetrix	0.1547843	2009	0.3347937

**Supplemental Table 6:** Contingency tables of differential gene expression classifications using a mixed-model nested ANOVA and an alpha cut-off of .001. In each cell the frequency, row percentage, and column percentage is reported, in that respective order. Probability values from Fisher's Exact Test of association and McNemar's test of agreement are also reported.

Table of Agilent by Affymetrix					
	Affyn	netrix			
Agilent	No	Yes	Total		
No	1917	25 <sup>+</sup>	1942		
	98.71	1.29			
	97.06	73.53			
Yes	58 <sup>+</sup>	9*	67		
	86.57	13.43			
	2.94				
Total	1975	34	2009		

Table of Amersham by Affymetrix					
	Affyn	netrix			
Amersham	No	Yes	Total		
No	1863	29+	1892		
	98.47	1.53			
	94.33	85.29			
Yes	112 <sup>+</sup>	5	117		
	95.73	4.27			
	5.67				
Total	1975	34	2009		

Table of Amersham by Agilent					
	Agi	lent			
Amersham	No	Yes	Total		
No	1848	44+	1892		
	97.67	2.33			
	95.16				
Yes	94+	23*	117		
	80.34	19.66			
	4.84				
Total	1942	67	2009		

Platform A	Platform B	Exact P-value for McNemar's Test	Fisher's Exact Test P-value (Right)
Agilent	Affymetrix	0.0004	<.0001
Amerhsam	Affymetrix	<.0001	0.0441
Amersham	Agilent	<.0001	<.0001

<sup>\*</sup> significant non-random association

<sup>&</sup>lt;sup>+</sup> significantly different detection rates

**Supplemental Table 7:** Contingency tables of differential gene expression classifications using a mixed-model nested ANOVA and an alpha cut-off of .001 and a 2-

fold minimum criterion. In each cell the frequency, row percentage, and column percentage is reported, in that respective order. Probability values from Fisher's Exact Test of association and McNemar's test of agreement are also reported.

Table of Agilent by Affymetrix				
	Affyn			
Agilent	No	Yes	Total	
No	1955	18	1973	
	99.09	0.91		
	98.39	81.82		
Yes	32	4*	36	
	88.89	11.11		
	1.61	18.18		
Total	1987	22	2009	

Table of Amersham by Affymetrix				
	Affyn			
Amersham	No	Yes	Total	
No	1933	20+	1953	
	98.98	1.02		
	97.28	90.91		
Yes	54 <sup>+</sup>	2	56	
	96.43	3.57		
	2.72			
Total	1987	22	2009	

Table of Amersham by Agilent				
	Agi			
Amersham	No	Yes	Total	
No	1933	20+	1953	
	98.98	1.02		
	97.97	55.56		
Yes	40+	16*	56	
	71.43	28.57		
	2.03			
Total	1973	36	2009	

Platform A	Platform B	Exact P-value for McNemar's Test	Fisher's Exact Test P-value (Right)
Agilent	Affymetrix	0.0649	0.0005
Amersham	Affymetrix	<.0001	0.1236
Amersham	Agilent	0.0135	<.0001

<sup>\*</sup> significant non-random association

<sup>&</sup>lt;sup>+</sup> significantly different detection rates

**Supplemental Table 8:** Contingency tables of differential gene expression classifications using a mixed-model nested ANOVA and an alpha cut-off of .01 and a 2-fold minimum criterion. In each cell the frequency, row percentage, and column percentage is reported, in that respective order. Probability values from Fisher's Exact Test of association and McNemar's test of agreement are also reported.

Table of Agilent by Affymetrix				
	Affyn	netrix		
Agilent	No	Yes	Total	
No	1878	65	1943	
	96.65	3.35		
	97.56 77.38			
Yes	47	19*	66	
	71.21	28.79		
	2.44			
Total	1925	84	2009	

Table of Amersham by Affymetrix				
	Affyn	netrix		
Amersham	No	Yes	Total	
No	1794	62+	1856	
	96.66	3.34		
	93.19	73.81		
Yes	131 <sup>+</sup>	22*	153	
	85.62	14.38		
	6.81			
Total	1925	84	2009	

Table of Amersham by Agilent				
	Agi	lent		
Amersham	No	No Yes		
No	1824	32+	1856	
	98.28   1.72			
	93.88			
Yes	119 <sup>+</sup>	34*	153	
	77.78 22.22			
	6.12			
Total	1943	66	2009	

Platform A	Platform B	Exact P-value for McNemar's Test	Fisher's Exact Test P-value (Right)
Agilent	Affymetrix	0.1078	<.0001
Amersham	Affymetrix	<.0001	<.0001
Amersham	Agilent	<.0001	<.0001

<sup>\*</sup> significant non-random association

<sup>&</sup>lt;sup>+</sup> significantly different detection rates

**Supplemental Table 9:** Contingency tables of differential gene expression classifications using a mixed-model nested ANOVA and an alpha cut-off of .001. The Affymetrix data was normalized using dChip. In each cell the frequency, row percentage, and column percentage is reported. Probability values from Fisher's Exact Test of association and McNemar's test of agreement are also reported.

Table of Agilent by Affymetrix				
	Affyn			
Agilent	No	Yes	Total	
No	1922 98.97 97.12	20 <sup>+</sup> 1.03 66.67	1942	
Yes	57 <sup>+</sup> 85.07 2.88	10* 14.93 33.33	67	
Total	1979	30	2009	

Table of Amersham by Affymetrix				
	Affymetrix			
Amersham	No	Yes	Total	
No	1875	17+	1892	
	99.10	0.90		
	94.74	56.67		
Yes	104+	13*	117	
	88.89	11.11		
	5.26	43.33		
Total	1979	30	2009	

Platform A	Platform B	Exact P-value for McNemar's Test	Fisher's Exact Test P-value (Right)
Agilent	Affymetrix	<.0001	<.0001
Amersham	Affymetrix	<.0001	<.0001

<sup>\*</sup> significant non-random association

<sup>&</sup>lt;sup>+</sup> significantly different detection rates

**Supplemental Table 10:** Contingency tables of differential gene expression classifications using a mixed-model nested ANOVA and an alpha cut-off of .001. The Affymetrix data was normalized using RMA. In each cell the frequency, row percentage, and column percentage is reported. Probability values from Fisher's Exact Test of association and McNemar's test of agreement are also reported.

Table of Agilent by Affymetrix			
	Affymetrix		
Agilent	No Yes		Total
No	1914	28+	1942
	98.56	1.44	
	97.11	73.68	
Yes	57 <sup>+</sup>	10*	67
	85.07	14.93	
	2.89	26.32	
Total	1971	38	2009

Table of Amersham by Affymetrix			
	Affymetrix		
Amersham	No	Yes	Total
No	1866	26+	1892
	98.63	1.37	
	94.67	68.42	
Yes	105+	12*	117
	89.74	10.26	
	5.33	31.58	
Total	1971	38	2009

Platform A	Platform B	Exact P-value for McNemar's Test	Fisher's Exact Test P-value (Right)
Agilent	Affymetrix	0.0022	<.0001
Amersham	Affymetrix	<.0001	<.0001

<sup>\*</sup> significant non-random association

<sup>&</sup>lt;sup>+</sup> significantly different detection rates

**Supplemental Table 11:** Classifications based upon Afffymetrix data normalized with dChip, RMA, and MAS5. Contingency tables of differential gene expression classifications using a mixed-model nested ANOVA and an alpha cut-off of .001. In each cell the frequency, row percentage, and column percentage is reported. Probability values from Fisher's Exact Test of association and McNemar's test of agreement are also reported.

Table of RMA by MAS5			
	MAS5		
	No	Yes	
No	1950	21	1971
	98.93	1.07	
	98.73	61.76	
Yes	25	13*	38
	65.79	34.21	
	1.27	38.24	
Total	1975	34	2009

Table of dChip by MAS5			
	MAS5		
dChip	No	Total	
No	1950	29	1979
	98.53	1.47	
	98.73	85.29	
Yes	25	5*	30
	83.33	16.67	
	1.27	14.71	
Total	1975	34	2009

Table of dChip by RMA			
	RMA		
dChip	No	Yes	Total
No	1952	27	1979
	98.64	1.36	
	99.04	71.05	
Yes	19	11*	30
	63.33	36.67	
	0.96	28.95	
Total	1971	38	2009

Platform A	Platform B	Exact P-value for McNemar's Test	Fisher's Exact Test P-value (Right)
RMA	MAS5	0.6587	<.0001
dChip	MAS5	0.6835	0.0001
dChip	RMA	0.3020	<.0001

<sup>\*</sup> significant non-random association


### **Supplemental Figure Legends**

**Supplemental Figure 1:** Scatter plots of log intensity values of the first and second experimental replicates.


**Supplemental Figure 2:** Scatter plots of log intensity values of the first and second biological replicates.


**Supplemental Figure 3:** Principal Components Analysis (PCA) of the data indicated that variation of signal values across microarray technologies was greater than signal variation caused by experimental treatment.


# **Supplemental Figure 1**




### **Supplemental Figure 2**








# PCA Mapping of Z-Transformed Data (72.5%)





# **References:**

- 1. Jolliffe, I.T. (1986) Principal Component Analysis. Springer-Verlag, New York, NY.
- 2. Affymetrix Inc. (2002) GeneChip Expression Analysis Data Analysis Fundamentals. (<a href="http://www.affymetrix.com/Auth/support/downloads/manuals/data\_analysis\_fundamentals\_manual.pdf">http://www.affymetrix.com/Auth/support/downloads/manuals/data\_analysis\_fundamentals\_manual.pdf</a>)